Terapia con Inibitori dell'SGLT2 nei Pazienti con Sindrome di Takotsubo Acuta.

BACKGROUND: SGLT2 inhibitors are approved for heart failure treatment, however, few data are available in patients with takotsubo syndrome (TTS). We aim to evaluate the safety, tolerability and effects of SGLT2 inhibitors therapy on myocardial recovery and inflammation in acute TTS. METHODS: We compared n = 22 SGLT2 inhibitors treated TTS patients (Dapagliflozin n = 13, Empagliflozin n = 9) with n = 44 1:2 propensity-score matched untreated. Treated patients were mostly consecutively enrolled after implementation of 2023 ESC heart failure guidelines. All underwent cardiac magnetic resonance (CMR) imaging with T2 mapping within 7 days of hospital admission. SGLT2 inhibitors were first admini